DALLAS, TX -- December 9th, 2022 -- Stonegate Healthcare has published a new report on Retinitis Pigmentosa (RP) and the pipeline of products in development. The report follows a recent webinar with ophthalmology experts, including a leading researcher and physician, Christine Kay, M.D., Vitreoretinal surgeon and IRD specialist at Vitreoretinal Associates, Eric Daniels, M.D., Chief Development Officer of Kiora Pharmaceuticals (NASDAQ: KPRX) and Ben Shaberman from the Foundation Fighting Blindness.
"There are currently more than 100 drugs in various stages of development for RP worldwide. Development of new treatments is largely being advanced by innovative biotechnology companies. This report breaks down the various approaches of gene therapy, cell therapy, optogenetics, and an emerging class of small molecule photoswitches and their potential to usher in a new era for patients.”